Home › Alcohol Use Disorder (AUD) › NCT07118618
Probenecid Administration for Alcohol Craving and Consumption
RecruitingPhase 2
Probenecid, Pannexin 1 Channels for Alcohol Use Disorder
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * • Male or female, ≥18 years. * women \>7 drinks/week; men \>14 drinks/week. * meet moderate to severe AUD score for DSM-5 criteria. * Breath Alcohol Content (BrAC)=0.00 at each visit. * in good health as confirmed by medical history, physical examination and lab tests. * willing to adhere to the study procedures. * understand informed consent and questionnaires in English at an 8th grade level. Exclusion Criteria: * • Women who are breastfeeding or positive urine test for pregnancy. * clinically significant medical abnormalities: unstable hypertension, clinically significant abnormal EKG, bilirubin \>150% of the upper normal limit, ALT/AST \>300% the UNL, creatinine clearance ≤60 dl/min * meet DSM-5 criteria for a diagnosis of schizophrenia, bipolar disorder, or other psychoses * medications that reduce alcohol consumption (naltrexone, disulfiram). * use aspirin (salicylates may reduce effect of probenecid), penicillin, methotrexate (may increase concentration). * history of suicide attempts in the last three years. * current diagnosis of a moderate or severe cannabis use disorder as assessed by self-report, SCID-E for SUD, and urine toxicology screen at baseline. * current diagnosis of another substance disorder at any severity, other than nicotine, as assessed by self-report, SCID-E for SUD, and urine toxicology screen at baseline. * current use of medications that may interact with probenecid. * history of hypersensitivity to sulfa drugs.
About the study
This study proposes a 16-week, between-subject, double-blind, randomized controlled trial (RCT) with probenecid (2g /day) compared to placebo in individuals with AUD to test if reduces craving and alcohol consumption.
What is being tested
- Probenecid Oral Tablet (drug)
- Placebo Oral Tablet (drug)
Sponsor: Brown University · Participants: 120 · Started: Mar 14, 2026
Contact the study team
- Brian Gully, MA · Phone: 401-863-6646
Official record on ClinicalTrials.gov — NCT07118618
Locations in the U.S.
| Rhode Island | Brown University, Providence |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.